Sangeun L.

SangEun L. is a highly experienced scientist currently serving as a Target Validation Scientist at Relation since March 2024. Prior to this role, SangEun worked at Mogrify from 2021 to March 2024 as a Scientist II, contributing to cell reprogramming therapeutic projects and engaging with external stakeholders. From January 2020 to September 2021, SangEun served as a Research Associate at the UCL Institute of Ophthalmology, focusing on antisense oligonucleotide-mediated therapy for retinal dystrophy using patient iPSC-derived retinal organoids. SangEun's academic foundation includes a PhD in Stem Cell and Cancer Biology from UCL (2015-2020), a Master of Research in Cell/Cellular and Molecular Biology from Imperial College London (2014-2015), and a Bachelor's degree in Molecular Biology from the same institution (2011-2014). Prior research experience at The Francis Crick Institute involved cancer and stem cell biology, particularly analyzing the Wnt pathway in colorectal cancer.